For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 0 | |||
| General and administrative | 5,745,087 | |||
| Research and development | 10,780,397 | |||
| Collaboration credits | 7,066,237 | |||
| In-process r&d impairment | 4,624,000 | |||
| Change in fair value of contingent consideration | -1,252,174 | |||
| Total operating expenses | 12,831,073 | |||
| Operating (loss) income before other income (expense), net | -12,831,073 | |||
| Impairment of intangible assets | 0 | |||
| Loss on disposal of fixed assets | 0 | |||
| Interest income | 894,002 | |||
| Interest expense | 19,960 | |||
| Other (expense) income, net | -160,272 | |||
| Total other income, net | 713,770 | |||
| (loss) income before income tax expense | -12,117,303 | |||
| Income tax benefit (expense) | -1,282,149 | |||
| Net (loss) income | -10,835,154 | |||
| Net (loss) income attributable to common shareholders, diluted | -10,835,154 | |||
| Basic EPS | -2.6 | |||
| Diluted EPS | -2.64 | |||
| Basic Average Shares | 4,166,692 | |||
| Diluted Average Shares | 4,103,873 | |||
KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC (KPRX)